AVITA Medical (RCEL) said Sunday that it has received CE Mark approval for its RECELL GO device, enabling it to commence sales in Europe and other CE-marked markets.
The company said that it will now roll out the device in select European countries, including Germany, Italy, and the UK, in collaboration with burn centers and clinical partners.
RECELL GO helps doctors use a small sample of a patient's skin to create a cell suspension that promotes healing in burns and wounds, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.